Wolverine Stack
Also known as: Wolverine Blend, BPC-157/TB-500 Stack, Healing Stack
Key Facts: Wolverine Stack
- Category
- Peptide Blend
- FDA Status
- Not FDA Approved
- Clinical Status
- Preclinical Research (Components)
- Administration
- Subcutaneous injection
- Typical Dose
- 250-500 mcg of each peptide daily
- Frequency
- Once or twice daily
- Duration
- 4-12 weeks depending on injury
Mechanism of Action
The two peptides are stacked because they are thought to hit different parts of the repair process. BPC-157, a 15-amino-acid sequence derived from a protein in gastric juice, appears to promote angiogenesis (new blood vessel growth) and upregulate growth factor and nitric oxide pathways in damaged tissue, at least in rodents. TB-500 is built around the actin-binding region of thymosin beta-4 and is proposed to drive cell migration, actin regulation, and recruitment of repair cells to the injury site. The popular framing is that BPC-157 improves blood supply while TB-500 mobilizes the cells that rebuild tissue. Both of these mechanisms come from preclinical models, not validated human pharmacology, so treat the synergy story as a hypothesis rather than proven.
Research Summary
There are no human randomized controlled trials of the Wolverine Stack as a combination, and there are no completed phase 2 or 3 trials of BPC-157 or TB-500 individually for tissue repair either. The evidence base is almost entirely rodent: BPC-157 has shown tendon, ligament, muscle, and gut healing effects in rats, and TB-500 (thymosin beta-4) has shown wound healing and cell migration effects in animal and cell models. Thymosin beta-4 itself reached human trials for conditions like pressure ulcers and dry eye, but those used the full protein, not the TB-500 fragment sold for stacks. What you read about the stack online is anecdote and clinic marketing, not controlled human data. In the United States, both peptides sit outside approved use, and as of 2026 they were removed from the FDA 503A compounding Category 2 list pending further review, so legitimate clinical access is limited. Anyone treating this as a proven recovery protocol is well ahead of the actual science.
Dosing Information
Note: Animal study doses may not translate directly to humans.
Typical Dosingⓘ
Community experience
250-500 mcg of each peptide daily
250-500 mcg BPC-157 + 250-500 mcg TB-500
Once or twice daily
Most popular healing stack. BPC-157 for local repair, TB-500 for systemic. Can inject near injury site.
Research Dosingⓘ
Scientific studies
Popular pre-mixed blend
Doses from Studies
BPC-157 10mg + TB-500 10mg per vial
Vendor Formulations - Standard commercial blend
Duration
4-12 weeks depending on injury
Administration
Subcutaneous injection
Timing & Administration
Best Time to Take
Morning or post-workout
Once or twice daily
Food Recommendation
With or without food
Why This Timing?
Align with natural healing cycles. Can inject near injury site for localized effects.
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Injection site reactions
- ●Mild headache (rare)
- ●Fatigue during initial use
- ●Nausea (rare)
References
- https://pmc.ncbi.nlm.nih.gov/articles/PMC6359621/
- https://pubmed.ncbi.nlm.nih.gov/29282567/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC2933142/
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3097006/
Research This Peptide Further
Frequently Asked Questions
What does Wolverine Stack do?
The Wolverine Stack is not a single drug. It is a popular nickname for combining two regenerative peptides, BPC-157 and TB-500 (a synthetic fragment of thymosin beta-4), usually injected together for injury recovery, tendon and soft-tissue repair, and inflammation. Neither peptide is FDA-approved for human use, and the combination itself has never been tested in a human clinical trial. Almost all supporting data is from animal studies on the individual peptides.
How does Wolverine Stack work?
The two peptides are stacked because they are thought to hit different parts of the repair process. BPC-157, a 15-amino-acid sequence derived from a protein in gastric juice, appears to promote angiogenesis (new blood vessel growth) and upregulate growth factor and nitric oxide pathways in damaged tissue, at least in rodents. TB-500 is built around the actin-binding region of thymosin beta-4 and is proposed to drive cell migration, actin regulation, and recruitment of repair cells to the injury site. The popular framing is that BPC-157 improves blood supply while TB-500 mobilizes the cells that rebuild tissue. Both of these mechanisms come from preclinical models, not validated human pharmacology, so treat the synergy story as a hypothesis rather than proven.
Is Wolverine Stack FDA approved?
No, Wolverine Stack is not currently FDA approved. Current status: Preclinical Research (Components)
What are the side effects of Wolverine Stack?
Reported side effects include: Injection site reactions, Mild headache (rare), Fatigue during initial use, Nausea (rare). Individual responses vary based on dosage, duration, and personal health factors.
What is the typical dose of Wolverine Stack?
Community-reported common dose: 250-500 mcg of each peptide daily (Once or twice daily). Range: 250-500 mcg BPC-157 + 250-500 mcg TB-500. Administration: Subcutaneous injection. Community-reported doses. Not medical advice. Consult healthcare provider.
Related Peptides
Peptides commonly compared with Wolverine Stack or used in similar applications.
Glow Protocol
PreclinicalGLOW (sometimes sold as Glow Blend) is a marketing name for a three-peptide cocktail: GHK-Cu (a copper-binding tripeptide), BPC-157, and TB-500. It is pitched for skin rejuvenation, collagen support, and tissue healing, usually as a single injectable blend from compounding clinics or research suppliers. None of the three peptides is FDA-approved for these uses, and the GLOW combination has never been studied as a product in any clinical trial.
Peptide BlendKLOW Blend
PreclinicalKLOW is a four-peptide blend that adds KPV to the GLOW mix, so it contains GHK-Cu, BPC-157, TB-500, and KPV. It is marketed for healing, anti-inflammatory, and skin and gut benefits, typically sold as a single research vial (commonly around 80 mg total). As with the other blends, none of the peptides is FDA-approved for these uses, and the KLOW combination has never been tested as a product in a clinical trial.
Peptide BlendBPC-157
PreclinicalBPC-157 is a synthetic 15-amino-acid peptide (sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) based on a fragment of a protective protein found in human gastric juice. It is studied almost entirely in animals for tendon, ligament, gut, and tissue healing, and it has racked up hundreds of preclinical papers. The catch: it is not approved by any regulator for any use, and the human evidence is a handful of small pilot studies, not real clinical proof.
HealingTB-500
PreclinicalTB-500 is a synthetic peptide that copies the active region of thymosin beta-4, a natural protein that controls how cells build and move their internal skeleton. Most TB-500 products reproduce the short LKKTETQ sequence (residues 17 to 23) responsible for binding actin and driving cell migration, which is why it gets marketed for tendon, muscle, and wound repair. Here is the honest part: there are essentially no completed human trials of the TB-500 fragment itself, and almost all the human clinical data is for the full-length thymosin beta-4 molecule, which is related but not the same thing.
HealingPentadecapeptide
PreclinicalPentadecapeptide almost always means BPC-157, a synthetic 15-amino-acid chain (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a protein found in human gastric juice. It is one of the most hyped 'healing' peptides online, marketed for tendon, gut, and muscle repair, but here is the catch: essentially all of the supporting evidence is from rats and mice. There is no FDA approval and no completed human clinical trial proving it does any of this.
HealingGHK-Cu
Clinical TrialsGHK-Cu is the copper(II) complex of GHK, a naturally occurring human tripeptide (glycyl-L-histidyl-L-lysine) found in blood plasma, saliva and urine, whose levels decline with age. It is researched and widely used in cosmetic skincare for skin regeneration, wound healing, collagen support and anti-aging. It is not an FDA-approved drug; it appears in over-the-counter cosmetics and as a research or compounded peptide, with most human evidence coming from small topical-skincare studies.
Skin & HairWant updates on Wolverine Stack research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.